Numerous previous studies have shown that acute myeloid leukemia (AML) patients under the age of 60 have around a 50% survival rate, while older patients have a worse prognosis, with around 15% survival. Poor treatment outcomes are often due to primary chemotherapy resistance and high relapse rates, emphasizing that standard chemotherapy is insufficient to cure most AML patients. More recently, many innovative approaches to drug design have been proposed, and drugs targeting the FMS-like tyrosine kinase 3 (FLT3) mutation or the iso-citrate dehydrogenase (IDH)-1 or -2 mutation have demonstrated significantly improved outcomes for AML patients. Targeted delivery of nanomedicines offers potential strategies to improve the efficacy of molecular drugs.
This Research Topic aims to collect studies identifying novel and potentially druggable pathways for the treatment of AML, including but not limited to nanoparticles, drug combination regimens, etc. Furthermore, unraveling the mechanisms of drug effects, especially the way in which immunity and metabolism are regulated, is also critical to overcoming treatment resistance and improving long-term survival outcomes. We welcome submissions covering but are not limited to the following:
1) Novel drug delivery systems for the treatment of AML, including nanoparticles, micelles, or other materials
2) New combination regimens for AML patients
3) Toxicity evaluation of natural and/or synthetic drugs in the blood system of AML patients
4) Exploration of drug application mechanisms (such as immunity, metabolism, proliferation, differentiation, apoptosis, autophagy, cell signaling pathways, etc.)
5) Novel natural or artificial agents for the treatment of AML
Please note:
• Manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with characterization of the dominating compound(s) are requested. The level of purity must be proven and included.
• Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Numerous previous studies have shown that acute myeloid leukemia (AML) patients under the age of 60 have around a 50% survival rate, while older patients have a worse prognosis, with around 15% survival. Poor treatment outcomes are often due to primary chemotherapy resistance and high relapse rates, emphasizing that standard chemotherapy is insufficient to cure most AML patients. More recently, many innovative approaches to drug design have been proposed, and drugs targeting the FMS-like tyrosine kinase 3 (FLT3) mutation or the iso-citrate dehydrogenase (IDH)-1 or -2 mutation have demonstrated significantly improved outcomes for AML patients. Targeted delivery of nanomedicines offers potential strategies to improve the efficacy of molecular drugs.
This Research Topic aims to collect studies identifying novel and potentially druggable pathways for the treatment of AML, including but not limited to nanoparticles, drug combination regimens, etc. Furthermore, unraveling the mechanisms of drug effects, especially the way in which immunity and metabolism are regulated, is also critical to overcoming treatment resistance and improving long-term survival outcomes. We welcome submissions covering but are not limited to the following:
1) Novel drug delivery systems for the treatment of AML, including nanoparticles, micelles, or other materials
2) New combination regimens for AML patients
3) Toxicity evaluation of natural and/or synthetic drugs in the blood system of AML patients
4) Exploration of drug application mechanisms (such as immunity, metabolism, proliferation, differentiation, apoptosis, autophagy, cell signaling pathways, etc.)
5) Novel natural or artificial agents for the treatment of AML
Please note:
• Manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with characterization of the dominating compound(s) are requested. The level of purity must be proven and included.
• Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
